Loading…

Pamicell announced it signed a supply contract for pharmaceutical intermediate nucleosides with Thermo Fisher Scientific, worth 1.86 billion KRW.
“Pamisel, a stem cell therapy research and development company, announced on the 19th that it has signed a supply contract for pharmaceutical intermediate nucleosides with Thermo Fisher Scientific.”asiae.co.kr
Summarized from public sources; check the original articles before acting on it.